



HAL
open science

Zika virus infection: an update

Pauline Ferraris, Hans Yssel, Dorothée Missé

► **To cite this version:**

Pauline Ferraris, Hans Yssel, Dorothée Missé. Zika virus infection: an update. *Microbes and Infection*, 2019, 21 (8-9), pp.353-360. 10.1016/j.micinf.2019.04.005 . hal-02959957

HAL Id: hal-02959957

<https://hal.umontpellier.fr/hal-02959957>

Submitted on 21 Jul 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 ZIKA VIRUS INFECTION: AN UPDATE

2

3 Pauline Ferraris¹, Hans Yssel² and Dorothée Missé^{1*}

4 ¹MIVEGEC, IRD, Univ. Montpellier, CNRS, Montpellier, France

5 ²Centre d'Immunologie et des Maladies Infectieuses, Inserm, U1135, Sorbonne Universités,

6 UPMC, APHP Hôpital Pitié-Salpêtrière, Paris, France

7 *Corresponding author: dorothee.misse@ird.fr

8

9 **Abstract**

10 Since the ZIKV outbreak in Brazil in 2015, the scientific community has joined efforts to
11 gather more information on the epidemiology, clinical features and pathogenicity of the virus.
12 Here, we summarize the most important advances made recently and discuss promising,
13 innovative approaches to understand and control ZIKV infection.

14 *Keywords* : Zika; Arbovirus; Vector control; Epidemiology; Innate immunity; Treatment

15

16

17

18

19

20

21 **1. Introduction**

22 Zika virus (ZIKV) is an emerging mosquito-borne Flavivirus, belonging to the *Flaviviridae*
23 family. ZIKV contains a positive single-stranded RNA encoding a polyprotein precursor that
24 is processed by cellular and viral proteases to yield its three structural proteins: the capsid (C),
25 the precursor of membrane (prM) and the envelop (E) proteins, as well as seven non-structural
26 protein: NS1 to NS5. ZIKV was discovered following scientific research on the enzootic
27 cycle of the Yellow fever virus and other unknown arboviruses in the Zika forest of Uganda.
28 The first case of human ZIKV infection has been reported in Uganda in 1952 [1] and the virus
29 was later isolated from humans in South East Asia [2]. Viral pathology was associated with a
30 few sporadic cases in tropical Africa and the south of Asia until 2007 when the number of
31 human cases of ZIKV infection unexpectedly increased, initially in Micronesia, then in
32 Pacific Ocean Island to finally reach the South American continent in 2015. Although the
33 reasons for the sudden emergence of the virus are not clear, several hypotheses can be put
34 forward. Many factors may determine the emergence of arboviruses, such as the actual
35 climate change, which affects the distribution of vectors, viral mutation frequency leading to
36 an increasing virulence, as well as changes in anthropological behaviour resulting in increased
37 host-pathogen interactions. ZIKV entry in Brazil from Pacific countries [3,4] has been linked
38 to two major social events, the World cup soccer game and the World Sprint Championships
39 [5] that were held in this country in 2014. At present, three different major lineages of ZIKV,
40 belonging to African, Asian and Brazilian strains, have been characterized according to
41 phylogenetic investigations. While Asian and Brazilian strains show low nucleotidics
42 differences, mutations have been highlighted between Asian strain and African strain.
43 Moreover, *in vitro* and *in vivo* studies revealed differential infection outcome, particularly
44 between the African and Asian/Brazilian strains, suggesting that the African strain seems to
45 be more virulent and to cause more cellular damage than the Asian/Brazilian strain [6–8].

46 Nonetheless, further investigations are needed to understand why both the Asian and Brazilian
47 strains are particularly associated with neurological disorders.

48

49 **2. Epidemiology**

50 **2.1 Geographic distribution**

51 Despite its broad geographical distribution, human infections with ZIKV have remained
52 sporadic and limited to small-scale epidemics for decades, until 2007 when a large epidemic
53 was reported on Yap Island with nearly 75% of the population being infected with the virus
54 [9]. Moreover, an outbreak of a syndrome due to ZIKV fever has been reported in French
55 Polynesia, associated with ZIKV-infection-related neurological and an unexpected increase in
56 the incidence of Guillain Barré syndrome by 20 fold [10]. Subsequently, several cases of
57 ZIKV infection in New Caledonia, Easter Island and the Cook Islands have been described
58 indicating a rapid spreading of the virus in the Pacific [3]. The ZIKV epidemic in 2015 has
59 been the start of an international public health emergency when the virus reaches the
60 American continent, with 33 countries reporting autochthonous transmission of ZIKV
61 infection and an increase in the incidence of cases of microcephaly and/or Guillain-Barré
62 syndrome. Moreover, ZIKV infection has also been associated with imported cases, notably in
63 Europe [11], indicating a rapid world-wide spread of the virus. On February 2016, the WHO
64 started to issue monthly reports on the situation of the ZIKV epidemy. On March 2017, the
65 WHO published the last report following the ZIKV outbreaks establishing a total of 61 areas
66 with ongoing virus transmission: 13 countries with evidence of person to person virus
67 transmission: 31 countries reporting neurological disorders associated with ZIKV infection
68 (microcephally, congenital malformations ...) and 23 countries reporting an increased
69 incidence of Guillain-Barré in ZIKV-infected patients (situation report, 10 March 2017,
70 WHO). During this period an estimate of 400 000 to 1.5 million cases of ZIKV infection have
71 been reported in these countries. Since 2017, the number of cases declined, although the virus

72 is still circulating in many countries, even in those that were not involved in the last outbreak.
73 For example, three laboratory-confirmed cases of ZIKV infection have been reported in India
74 (Bapunagar area) showing that the virus is still circulating in this country (Disease Outbreak
75 News, 26 May 2017, WHO). For several years, new informatic tools have been developed to
76 improve the modelisation of infectious disease outcome. As a consequence, many studies
77 have been performed to develop predictive models of ZIKV spread by taking into account
78 determining parameters of the infection (vector abundance, local temperature, mode of
79 transmission, surveillance information and human behavior) to obtain meaningful projections
80 of the number of ZIKV infections in countries around the world [12,13]. These models will
81 allow public health authorities to better anticipate the propagation of ZIKV infection or to
82 project the end of the epidemy.

83

84 **2.2 Transmission and vector control**

85 The main mode of ZIKV transmission occurs via the female mosquito bite during blood
86 feeding, although the human to human transmission route, among which perinatal
87 transmission [14], sexual transmission [15,16] and breast milk feeding [17–19] has been
88 described as well. Many different species of *Aedes* mosquito can account for the transmission
89 of ZIKV, including *Ae.aegypti* and *albopictus* [20,21]. Nevertheless, the competence of this
90 two *Aedes* genus seems to be variable according to geographic sites and the viral strain it has
91 been infected with [22,23]. The *Aedes* genus is dispersed in predominantly tropical areas on
92 three continents (Asia, Africa, America), but shows increased spreading, particularly in North
93 America, Europe and China [24], which highlights the importance to develop efficient tools to
94 control the spread of the vectors. Strategies to contain and reduce the development of
95 mosquito populations have already been established to limit arbovirus propagation (**Figure**
96 **1**). To this aim, the WHO promotes a combination of methods, such as individual and
97 household protection (clothing, air-conditioning, repellents, net ...), procedures to limit

98 backwater and the safe use of insecticides. However, these methods are not sufficient to halt
99 vector-borne disease spread and there is a real need for innovative, efficacious, approaches.
100 Recently, the Worldwide Insecticide resistance Network (WIN) [25] symposium
101 (<https://www.winsingapore2018.com/>) has provided an overview of the alternative methods
102 currently under development for the control of arbovirus vectors [26–28]. Amongst these new
103 tools feature novel larvicides (entomopathogenic Ascomycetes fungi, pyroproxifen,
104 autodissemination), classical and biotechnology-based sterile insect techniques, spatial
105 repellents, insect traps, attractive targeted sugar baits, insecticide-treated materials and gene
106 drives (ex : CRISPR-Cas like system C2c2). Moreover, an emerging method showing
107 impressive results to prevent arbovirus propagation is the use of the bacterial *Wolbachia*
108 genus to either eliminate *Ae.aegypti* mosquito (mosquito population suppression) [29,30] or
109 restrict the arbovirus infection (i.e. mosquito population replacement) [31]. In fact, it has
110 been shown that the endosymbiotic bacterium *Wolbachia*, naturally present in up to 40% of
111 all arthropods [32] is able to block the transmission of many human pathogens in mosquitoes,
112 such as CHIKV, DENV and Plasmodium [33,34], by cytoplasmic incompatibility [35]. More
113 recently, several experimental studies showed that the wMel *Wolbachia* strain is able to also
114 restrict ZIKV infection in *Ae. aegypti* [36–38]. Nevertheless these methods show efficacy
115 limits and ethical issues and need to also integrate a sustainable, effective, community-based,
116 locally adapted vector control management to reduce the burden of *Aedes*-transmitted disease
117 [27].

118 ZIKV outbreaks have mainly been investigated in countries where the infection was
119 associated with severe symptoms. Nevertheless, it remains important to provide more
120 information about the prevalence of the infection in other countries where the virus is
121 circulating, or has circulated probably with more asymptomatic effects, to better understand
122 the evolutive propagation of the virus. In particular it is of importance to define and

123 characterize the different factors that are associated with its emergence and pathogenicity and
124 in this respect, it appears crucial to obtain more information about the circulation and
125 infection outcome of ZIKV in Africa and India where the virus has started its course.

126

127 **3. Pathogenicity of ZIKV in humans**

128 **3.1 Symptoms of Zika virus infection**

129 The sudden emergence of ZIKV has rapidly become a major public health due to the severe
130 symptoms developed by newborn babies. In fact, the latest outbreak has raised major
131 concerns about the pathogenicity of ZIKV since severe neurological complications in fetuses,
132 neonates and adults were found to be associated with the infection [39–41]. Previous outbreaks
133 of ZIKV were characterized by a classic clinical pattern, fever, rash, arthralgia and
134 conjunctivitis in infected individuals [42]. However, in ZIKV-infected pregnant women in
135 Brazil, a remarkable 42% of fetuses exhibited some type of ultrasound abnormality [43]. The
136 clinical phenotype of congenital ZIKV infection was variable and included cerebral
137 calcifications, microcephaly, intrauterine growth restriction and fetal demise. Computed
138 tomography and magnetic resonance imaging of the brains of congenitally infected neonates
139 in Brazil further demonstrated hypoplasia of the cerebellum and brainstem, ventriculomegaly,
140 delayed myelination, enlarged cisterna magna, abnormalities of the corpus callosum,
141 calcifications, and cortical malformations [44]. It is of note that retrospective assessment of
142 the ZIKV epidemic in French Polynesia also found an increased risk of microcephaly
143 associated with ZIKV infection, with 95 cases occurring per 10,000 women infected in the
144 first trimester [45]. In comparison to the encephalitic flaviviruses (e.g., West Nile virus and
145 Tick-borne encephalitis virus), ZIKV generally is less neuroinvasive in adults, rarely causing
146 meningitis and encephalitis [46]. ZIKV infection has also been associated with the
147 development of Guillain-Barré Syndrome (GBS) in a lower percentage of patients

148 [10,39,47,48]. GBS is an auto-immune disease associated with aberrant inflammation that
149 targets peripheral nerves and leading to muscle weakness and paralysis [49]. It is
150 hypothesized that the production of neutralizing antibodies against ZIKV target peripheral
151 nerve glycolipids, thereby inducing injuries of myelin or axonal membranes that leads to
152 inflammatory demyelinating polyneuropathy [49–51]. Further research is needed to better
153 characterized the immune response mechanism involved in the GBS development associated
154 with ZIKV infection.

155

156 **3.2 Zika virus permissiveness and replication**

157 The epidemic of Zika in Brazil has been followed by an exceptional effort from the scientific
158 community to identify the key biological factors associated with the pathogenicity of the virus
159 and to help the health system to contain the epidemic. ZIKV infection studies using patients
160 samples, *in vivo* and *in vitro* models [52,53] allowed to characterized different tissue and cell
161 lines permissive to infection. ZIKV has been detected in placenta, brain, eye, testis, uterus,
162 vagina and body fluids (blood, tears, saliva, semen, cervical mucus and urine) in human [54],
163 but also in liver, spleen, lung, kidney, heart and muscle in various animal models [55–59].
164 Moreover, *in vitro* studies characterized a broad range of cell lines showing differential
165 susceptibility to ZIKV infection, providing new tools to study its pathogenesis [60,61].
166 Interestingly, cell lines derived from the placenta or genital tract are susceptible to infection
167 with ZIKV, but not with other while other flaviviruses, such as DENV [61] which could
168 explain the association of ZIKV with congenital disorders. In addition, ZIKV was found to
169 replicate in human testicular tissue and male germ cells and furthermore persisted in semen
170 [62,63] resulting in a high risk of sexual transmission. More precisely, a recent study
171 investigating ZIKV dissemination in the male reproductive tract proposed a model in which
172 ZIKV infects the testis through the hematogenous route, whereas infection of the epididymis

173 can occur through both hematogenous/lymphogenous and excurrent testicular routes [64].
174 Nevertheless, ZIKV preferentially infects brain cells, in particular human neural progenitor
175 cells (hNPC) [65–68], which may explain its ability to impair development of the fetal brain
176 and cause microcephaly and other neurodevelopmental injuries. ZIKV-induced microcephaly
177 can have several different causes [69] since the virus can affect the neuronal progenitors
178 which results in either cell death or neurogenesis dysregulation [66,67,70]. ZIKV can also
179 infect glial cells and disturb their role in neuronal development. In addition, it is yet unknown
180 if these mechanisms could vary according to viral strain, being from African or Asian origin.
181 Like all viruses, ZIKV depends heavily on the cellular machinery of the host to accomplish its
182 life cycle. The permissiveness of ZIKV is dependent on the presence of specific cell surface
183 receptors which allow the entry of the virus in the cells. Several entry receptors have already
184 been identified to facilitate ZIKV infection, including the innate immune receptor DC-SIGN,
185 TIM-1 and TAM receptors (transmembrane protein TYRO-3, AXL and MER) in human skin
186 cells, endothelial cells, neural and retinal progenitor cells, highlighting a unique tropism
187 among flaviviruses [60,42,71–75]. More recently, high-throughput fitness profiling of ZIKV
188 E protein has shown that N-linked glycosylation enhances ZIKV infection in mammalian cell
189 line following interaction with DC-SIGN [76]. Several studies in experimental mouse models
190 have also shown that TAM receptors, in particularly AXL, are determinant, although not
191 essential, for ZIKV infection [77,78]. Further investigations are still needed to clarify the role
192 of each of each of these receptors and to identify any additional key entry factors that could
193 represent an potential new therapeutic target.

194

195 **3.3 Innate immune response to ZIKV**

196 ZIKV infection induces innate and adaptative responses by infected cells. First, viral RNA
197 sensors activate TLR receptors, in particularly TLR3 and TLR7, as well as the RIG-like

198 receptors MDA5 and RIG-I, leading to the production of type I (IFN- β) and type III (IFN-
199 λ) interferons. The latter will then bind their respective receptors to induce the activation of
200 the JAK/STAT signaling pathway leading to the production of interferon-stimulated genes,
201 such as ISG15, OAS2, MX1, and IFIT, as well as inflammatory chemokines, like CCL5 and
202 CXCL10 [42,79]. Moreover, recent reports have also highlighted the importance of IFITM1
203 and IFITM3, members of the family of interferon-inducible transmembrane proteins, in the
204 inhibition of ZIKV replication [80,81] and the prevention of ZIKV-induced cell death [81].
205 The importance of IFN signaling pathway has been highlighted by the development of ZIKV-
206 induced pathology in mice deficient in the expression of type I and II IFN receptors or
207 STAT2 that was not observed in immunocompetent mice [56,58,53,82]. Moreover, IFN- λ has
208 been shown to be particularly protective against ZIKV infection in the female reproductive
209 tract [83] and in the maternal decidua and placenta associated with its production at later
210 gestational stages during pregnancy [84,85]. Therefore, differential innate immune response
211 profiles according to cell type and cell differentiation state associated with immunological
212 maturation could be related to variable susceptibility to ZIKV infection [83–85] (Ferraris et
213 al., unpublished data).

214 ZIKV, as many other viruses, is able to counteract anti-viral immune responses through the
215 interaction of viral proteins with proteins of cellular signalling. In particular, ZIKV is able to
216 impair IFNs signaling pathways [86] by preventing STAT1 phosphorylation [87], inducing
217 JAK1 and STAT2 proteasomal degradation through its interaction with the NS2B-NS3
218 protease [88] and NS5 [89], respectively. Moreover, the NS2B-NS3 protease complex is
219 also able to target the human STING protein [90] whereas NS1 and NS4B reduce IFN- β
220 production by disrupting phospho-TBK1 in human brain cells [91].

221 ZIKV sfRNA, a subgenomic viral RNA, is also involved in viral interference with innate
222 immune responses [92], since it has been reported to antagonize RIG-I mediated induction of

223 type I interferon in human lung epithelial cells [93,94]. More recently, the FXMRP protein,
224 identified as restricted factor of ZIKV, has been shown to be antagonized by ZIKV sfRNA
225 [95].

226 The immune response is essential to fight infection **but can** also be associated with
227 pathogenesis by inducing auto-immune disease. Within this context, it has been shown that
228 ZIKV can induce exacerbated neuro-inflammation associated with NPC depletion in human
229 organoids, notably through the activation of TLR3 [96] and production of cytokines [97].
230 Moreover, the production of non-neutralizing antibodies that induce a process called
231 Antibody-Dependent Enhancement during a primary infection against DENV can facilitate
232 the infection by another flavivirus through the cross-reactivity with the Fcγ receptor [98].
233 Because of the important ZIKV outbreak in countries where DENV is known to be epidemic,
234 many **studies have been performed to evaluate this cross-reactivity between both viruses [99].**
235 **However, the results remain controversial, whereas some studies found that prior DENV**
236 **infection was associated with lower risk to develop ZIKV infection symptoms [100,101],**
237 **other *in vitro* and *in vivo* studies reported opposite observations [98,102,103]. This**
238 **phenomenon seems to be dependent on the virus strain and host immune response, and needs**
239 **to be taken in account in the development of an anti-ZIKV vaccine [104].**

240 **Since the ZIKV outbreak in 2015 an exceptional effort has been made to develop fundamental**
241 **research aimed to improve our knowledge about the biology of this flavivirus, including its**
242 **tropism, morphogenesis and antiviral responses. These studies have been essential to better**
243 **understand the infection and to implement novel approaches for treatment and the**
244 **development of vaccines. These advances notwithstanding, continued investigations are still**
245 **needed to understand the molecular mechanisms underlying the capacity of the virus to cross**
246 **the placental and blood-brain barrier, unlike other flaviviruses, as well as the differences**

247 between the various ZIKV strains and the impact of co-infection with other arboviruses on
248 viral pathogenicity.

249

250 4. Treatment and vaccine perspectives

251 4.1 Antiviral molecules

252 Currently, no vaccines or antiviral treatments have been approved to cure ZIKV infection and
253 patients' care is mainly focused on treating their symptoms. The main challenge is to develop
254 treatment for ZIKV infection that can be administrated to pregnant women. Nevertheless,
255 hundreds of compounds are currently tested *in silico* for their capacity to interfere with the
256 replicative life cycle of ZIKV, but only few have been shown to inhibit ZIKV infection *in*
257 *vitro* and need further testing *in vivo* as well as in clinical trials (**Table 1**) (**Figure 1**) [105–
258 107]. Some molecules, called Direct Acting Agents have the potential to directly act on viral
259 function by inhibiting both early and late stages of replication. Another antiviral strategy is to
260 block viral entry by inhibiting the attachment, endocytosis and fusion of the virus in the cell.
261 Several molecules show encouraging *in vitro* results such as duramycin and suramin that may
262 prevent attachment to host receptors mediating flavivirus entry into the cell [108–110] and
263 nanchangmycin that seems to block clathrine-mediated endocytosis of ZIKV [111].
264 Nevertheless, no *in vivo* studies have been published so far that sustain their efficacy. *In vivo*
265 experiments demonstrated that two inhibitors of ZIKV entry, a synthetic peptide inhibitor, Z2,
266 interfered with vertical transmission of ZIKV in pregnant mice [112] and Cholesterol-25-
267 hydroxylase, a natural interferon stimulated gene, responsible for cholesterol oxydation
268 inhibiting ZIKV uptake, are protective against ZIKV symptoms and microcephaly [113].
269 These molecules need now to be tested in clinical trials. Another strategy consists in the
270 targeting of the NS2B-NS3 viral protease protein which allows the cleavage of the different
271 viral proteins from the polyprotein. Therefore Novobiocin, lopinavir-ritonavir and

272 Bromocriptine, among other molecules, show a significant effect on ZIKV infection and cell
273 death *in vitro* or *in silico*, via the inhibition of protease activity [114,115]. Another targeted
274 viral protein is NS5 RdRp whose polymerase activity is crucial for the replication of the virus.
275 One of the promising molecules is the Sofosbuvir a class B FDA-approved compound that has
276 already been tested to treat Hepatitis C virus infections. Importantly, animal studies have not
277 demonstrated a risk to use it during pregnancy. The efficacy of Sofosbuvir to inhibit ZIKV
278 infection has been demonstrated *in vitro* in neural progenitor cells, brain organoids,
279 neuroepithelial stem cells and *in vivo* in mice [91,116–118]. Other viral protein are targeted to
280 identify new potential drugs, such as NS3 helicase (Ivermectin and Resveratrol) and NS5
281 methyltransferase for which compounds have shown antiviral activity against other
282 flaviviruses and therefore will need to be tested on ZIKV infection [107]. Many other
283 compounds which show a conserved efficacy among flaviviruses could represent a potential
284 target for ZIKV and need to be tested as well. Several other molecules that are currently under
285 development are tested to counteract undesirable cell effects that could be induced by the
286 virus. For example, Emericansan has been shown to reduce cellular apoptosis by inhibiting
287 caspase-3 activity, whereas several nucleoside analogues are able to reduce cytopathic effects
288 and cell death after ZIKV infection [119]. Moreover, some modulators of lipid metabolism
289 such as Imipramine, an FDA approved drug, inhibits ZIKV replication and viral production,
290 in human skin fibroblasts, probably through interference with intracellular cholesterol
291 transport [120]. More recently, Taguwa et al. highlighted the interest to target the cellular
292 protein Hsp70, essential for flavivirus replication for antiviral strategy. They showed that
293 Hsp70 inhibitor, significantly reduced ZIKV replication in cells, associated with reducing
294 pathogenicity in mice and low cytotoxicity effect. Furthermore Hsp70 inhibitors present a low
295 risk of drug resistance makes them new attractive antivirals against ZIKV infection [121].
296 Finally, therapeutic antibodies could be also an alternative since the results of several studies

297 have shown that neutralizing antibodies targeting ZIKV can prevent viral replication,
298 microcephally and fetal disease in mice [122–124].

299

300 4.2 Vaccines

301 Following the sudden outbreak of ZIKV infection in Brazil, the international health care
302 system has called for the development of candidate vaccines against the virus. One of the
303 important challenge of ZIKV vaccine development is to produce a low cost and safe vaccine
304 to be inoculated in pregnant women, particularly in low-ressource countries where viral
305 outbreaks occur. Several mouse and rhesus monkey models have been established in the
306 framework of ZIKV vaccine development [58,53,125,126]. Most models used to study ZIKV
307 vaccine efficacy are knockout mice (129, C57BL/6, Balbc, Swiss...) with deficiencies in IFN
308 type I (IFN- α and - β) or II (IFN- γ) receptors which have the particularity to reproduce several
309 characteristics of ZIKV pathogenesis, such as fever, neurological disorders on newborn
310 mouse and lethality. Many vaccine subtypes and strategies are under development and
311 vaccine candidates are currently tested for their non-toxicity and efficacy, although only a few
312 are currently in phase I or II clinical trials (**Table 1**) (**Figure 1**) [125,127,128]. Among the
313 more promising vaccines in clinical trials there is a ZIKV-purified inactivated virus (ZPIV)
314 which was found to confer long-term protection in monkeys [129,130] and several nucleic
315 acid vaccines targeting the prM and E proteins that provide complete protection against viral
316 challenges in both mice and non human primates [129–134] as well as an adenovirus-based
317 vaccine targeting the prM and E protein of ZIKV with a complete long-term protection in
318 monkeys [129,135]. Additional vaccines are also being investigated but are still in the process
319 of preclinical development [125,127,128,136]. Also, fundamental research has higlighted a
320 new and very interesting strategy, pertaining to as an miRNA co-targeting approach for a live
321 virus vaccine that might result in improved genetic stability and restricted virus replication

322 [64]. In summary, remarkable efforts have been undertaken to develop an effective vaccine
323 against ZIKV infection and a list of potential candidates has been identified of which several
324 have reached phase II in clinical trials.

325 5. Conclusion

326 Three years after the beginning of the ZIKV outbreak in Brazil, the virus is still subject to
327 intense medical research. Many investigations have allowed to better understand the biology
328 of the infection leading to the establishment of vector control strategies and the development
329 of drugs and vaccines that are currently tested in clinical trials in a remarkably short time
330 following the outbreak (**Figure 1**). Nevertheless, most of the challenges such as vector
331 control, diagnostics and patients care need to be improved in order to better control ZIKV
332 spread. The symptomatic consequences of the co-circulation of ZIKV with other arboviruses
333 such as DENV and CHIKV are still poorly characterized. However, since both viruses use the
334 same vector it is important to continue to put a main effort in strategies of vector control. The
335 latest ZIKV outbreak also highlights the importance to develop better tools to survey the
336 circulation of arboviruses in general and prevent the emergence of new ones. *In fine*, lessons
337 from ZIKV outbreak have to be integrated to be prepared to adequately respond to the
338 emergence of the next generation of arboviruses already circulating in the vector [137].

339

340 Acknowledgements

341 This work was supported by grants from the Agence Nationale de la Recherche (grants ANR-
342 ANR-14-CE14-0029 and ANR-15-CE15-00029), the European Union's Horizon 2020
343 research and innovation programme under ZIKAlliance grant agreement No. 734548. This
344 work was also publicly funded through the French National Research Agency under the
345 "Investissements d'avenir" programme with the reference ANR-16-IDEX-0006.

346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389

References :

[1] Moore DL, Causey OR, Carey DE, Reddy S, Cooke AR, Akinkugbe FM, et al. Arthropod-borne viral infections of man in Nigeria, 1964-1970. *Ann Trop Med Parasitol* 1975;69:49–64.

[2] Darwish MA, Hoogstraal H, Roberts TJ, Ghazi R, Amer T. A sero-epidemiological survey for Bunyaviridae and certain other arboviruses in Pakistan. *Trans R Soc Trop Med Hyg* 1983;77:446–50.

[3] Musso D, Nilles EJ, Cao-Lormeau V-M. Rapid spread of emerging Zika virus in the Pacific area. *Clin Microbiol Infect* 2014;20:O595-596. doi:10.1111/1469-0691.12707.

[4] Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, et al. Zika virus: History, emergence, biology, and prospects for control. *Antiviral Res* 2016;130:69–80. doi:10.1016/j.antiviral.2016.03.010.

[5] Zanluca C, Melo VCA de, Mosimann ALP, Santos GIV dos, Santos CND dos, Luz K. First report of autochthonous transmission of Zika virus in Brazil. *Memórias Do Instituto Oswaldo Cruz* 2015;110:569–72. doi:10.1590/0074-02760150192.

[6] Anfasa F, Siegers JY, van der Kroeg M, Mumtaz N, Stalin Raj V, de Vrij FMS, et al. Phenotypic Differences between Asian and African Lineage Zika Viruses in Human Neural Progenitor Cells. *mSphere* 2017;2. doi:10.1128/mSphere.00292-17.

[7] Simonin Y, van Riel D, Van de Perre P, Rockx B, Salinas S. Differential virulence between Asian and African lineages of Zika virus. *PLOS Neglected Tropical Diseases* 2017;11:e0005821. doi:10.1371/journal.pntd.0005821.

[8] Hamel R, Ferraris P, Wichit S, Diop F, Talignani L, Pompon J, et al. African and Asian Zika virus strains differentially induce early antiviral responses in primary human astrocytes. *Infection, Genetics and Evolution* 2017;49:134–7. doi:10.1016/j.meegid.2017.01.015.

[9] Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika Virus Outbreak on Yap Island, Federated States of Micronesia. *New England Journal of Medicine* 2009;360:2536–43. doi:10.1056/NEJMoa0805715.

[10] Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, et al. Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013. *Euro Surveill* 2014;19.

[11] Zammarchi L, Tappe D, Fortuna C, Remoli ME, Günther S, Venturi G, et al. Zika virus infection in a traveller returning to Europe from Brazil, March 2015. *Euro Surveill* 2015;20.

[12] Lo D, Park B. Modeling the spread of the Zika virus using topological data analysis. *PLOS ONE* 2018;13:e0192120. doi:10.1371/journal.pone.0192120.

[13] O’Reilly KM, Lowe R, Edmunds WJ, Mayaud P, Kucharski A, Eggo RM, et al. Projecting the end of the Zika virus epidemic in Latin America: a modelling analysis. *BMC Medicine* 2018;16. doi:10.1186/s12916-018-1158-8.

[14] Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. *Euro Surveill* 2014;19.

- 390 [15] D’Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Piorkowski G, et al.
391 Evidence of Sexual Transmission of Zika Virus. *N Engl J Med* 2016;374:2195–8.
392 doi:10.1056/NEJMc1604449.
- 393 [16] Sakkas H, Bozidis P, Giannakopoulos X, Sofikitis N, Papadopoulou C. An Update on Sexual
394 Transmission of Zika Virus. *Pathogens* 2018;7:66. doi:10.3390/pathogens7030066.
- 395 [17] Blohm GM, Lednicky JA, Márquez M, White SK, Loeb JC, Pacheco CA, et al. Evidence for Mother-
396 to-Child Transmission of Zika Virus Through Breast Milk. *Clinical Infectious Diseases*
397 2018;66:1120–1. doi:10.1093/cid/cix968.
- 398 [18] Mann TZ, Haddad LB, Williams TR, Hills SL, Read JS, Dee DL, et al. Breast milk transmission of
399 flaviviruses in the context of Zika virus: A systematic review. *Paediatric and Perinatal*
400 *Epidemiology* 2018;32:358–68. doi:10.1111/ppe.12478.
- 401 [19] Colt S, Garcia-Casal MN, Peña-Rosas JP, Finkelstein JL, Rayco-Solon P, Weise Prinzo ZC, et al.
402 Transmission of Zika virus through breast milk and other breastfeeding-related bodily-fluids: A
403 systematic review. *PLOS Neglected Tropical Diseases* 2017;11:e0005528.
404 doi:10.1371/journal.pntd.0005528.
- 405 [20] Grard G, Caron M, Mombo IM, Nkoghe D, Mboui Ondo S, Jiolle D, et al. Zika Virus in Gabon
406 (Central Africa) – 2007: A New Threat from *Aedes albopictus*? *PLoS Neglected Tropical Diseases*
407 2014;8:e2681. doi:10.1371/journal.pntd.0002681.
- 408 [21] Boyer S, Calvez E, Chouin-Carneiro T, Diallo D, Failloux A-B. An overview of mosquito vectors of
409 Zika virus. *Microbes and Infection* 2018. doi:10.1016/j.micinf.2018.01.006.
- 410 [22] Chouin-Carneiro T, Vega-Rua A, Vazeille M, Yebakima A, Girod R, Goindin D, et al. Differential
411 Susceptibilities of *Aedes aegypti* and *Aedes albopictus* from the Americas to Zika Virus. *PLoS*
412 *Negl Trop Dis* 2016;10:e0004543. doi:10.1371/journal.pntd.0004543.
- 413 [23] Garcia-Luna SM, Weger-Lucarelli J, Rückert C, Murrieta RA, Young MC, Byas AD, et al. Variation
414 in competence for ZIKV transmission by *Aedes aegypti* and *Aedes albopictus* in Mexico. *PLOS*
415 *Neglected Tropical Diseases* 2018;12:e0006599. doi:10.1371/journal.pntd.0006599.
- 416 [24] Kraemer MUG, Sinka ME, Duda KA, Mylne AQN, Shearer FM, Barker CM, et al. The global
417 distribution of the arbovirus vectors *Aedes aegypti* and *Ae. albopictus*. *Elife* 2015;4:e08347.
418 doi:10.7554/eLife.08347.
- 419 [25] Corbel V, Achee NL, Chandre F, Coulibaly MB, Dusfour I, Fonseca DM, et al. Tracking Insecticide
420 Resistance in Mosquito Vectors of Arboviruses: The Worldwide Insecticide resistance Network
421 (WIN). *PLOS Neglected Tropical Diseases* 2016;10:e0005054.
422 doi:10.1371/journal.pntd.0005054.
- 423 [26] Achee NL, Grieco JP, Vatandoost H, Seixas G, Pinto J, NG LC, et al. Alternative Strategies for
424 Arbovirus Control. *PLOS Neglected Tropical Diseases* 2018.
- 425 [27] Roiz D, Wilson AL, Scott TW, Fonseca DM, Jourdain F, Müller P, et al. Integrated *Aedes*
426 management for the control of *Aedes*-borne diseases. *PLOS Neglected Tropical Diseases*
427 2018;12:e0006845. doi:10.1371/journal.pntd.0006845.
- 428 [28] Singh RK, Dhama K, Khandia R, Munjal A, Karthik K, Tiwari R, et al. Prevention and Control
429 Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector
430 Mosquitoes—Current Updates. *Frontiers in Microbiology* 2018;9.
431 doi:10.3389/fmicb.2018.00087.
- 432 [29] Mains JW, Brelsfoard CL, Rose RI, Dobson SL. Female Adult *Aedes albopictus* Suppression by
433 *Wolbachia*-Infected Male Mosquitoes. *Scientific Reports* 2016;6. doi:10.1038/srep33846.
- 434 [30] Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, Muzzi F, et al.
435 Successful establishment of *Wolbachia* in *Aedes* populations to suppress dengue transmission.
436 *Nature* 2011;476:454–7. doi:10.1038/nature10356.
- 437 [31] Flores HA, O’Neill SL. Controlling vector-borne diseases by releasing modified mosquitoes.
438 *Nature Reviews Microbiology* 2018;16:508–18. doi:10.1038/s41579-018-0025-0.
- 439 [32] Zug R, Hammerstein P. Still a Host of Hosts for *Wolbachia*: Analysis of Recent Data Suggests
440 That 40% of Terrestrial Arthropod Species Are Infected. *PLoS ONE* 2012;7:e38544.
441 doi:10.1371/journal.pone.0038544.

- 442 [33] Bian G, Joshi D, Dong Y, Lu P, Zhou G, Pan X, et al. Wolbachia Invades Anopheles stephensi
443 Populations and Induces Refractoriness to Plasmodium Infection. *Science* 2013;340:748–51.
444 doi:10.1126/science.1236192.
- 445 [34] Moreira LA, Iturbe-Ormaetxe I, Jeffery JA, Lu G, Pyke AT, Hedges LM, et al. A Wolbachia
446 Symbiont in *Aedes aegypti* Limits Infection with Dengue, Chikungunya, and Plasmodium. *Cell*
447 2009;139:1268–78. doi:10.1016/j.cell.2009.11.042.
- 448 [35] Werren JH, Baldo L, Clark ME. Wolbachia: master manipulators of invertebrate biology. *Nature*
449 *Reviews Microbiology* 2008;6:741–51. doi:10.1038/nrmicro1969.
- 450 [36] Dutra HLC, Rocha MN, Dias FBS, Mansur SB, Caragata EP, Moreira LA. Wolbachia Blocks
451 Currently Circulating Zika Virus Isolates in Brazilian *Aedes aegypti* Mosquitoes. *Cell Host &*
452 *Microbe* 2016;19:771–4. doi:10.1016/j.chom.2016.04.021.
- 453 [37] Schultz MJ, Isern S, Michael SF, Corley RB, Connor JH, Frydman HM. Variable Inhibition of Zika
454 Virus Replication by Different Wolbachia Strains in Mosquito Cell Cultures. *Journal of Virology*
455 2017;91. doi:10.1128/JVI.00339-17.
- 456 [38] Schultz MJ, Tan AL, Gray CN, Isern S, Michael SF, Frydman HM, et al. *Wolbachia w* Stri Blocks
457 Zika Virus Growth at Two Independent Stages of Viral Replication. *MBio* 2018;9.
458 doi:10.1128/mBio.00738-18.
- 459 [39] Cao-Lormeau V-M, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré
460 Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control
461 study. *Lancet* 2016;387:1531–9. doi:10.1016/S0140-6736(16)00562-6.
- 462 [40] Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj M, Mraz J, et al. Zika Virus Associated with
463 Microcephaly. *New England Journal of Medicine* 2016;374:951–8.
464 doi:10.1056/NEJMoa1600651.
- 465 [41] Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. *The*
466 *Lancet* 2017;390:2099–109. doi:10.1016/S0140-6736(17)31450-2.
- 467 [42] Hamel R, Liégeois F, Wichit S, Pompon J, Diop F, Talignani L, et al. Zika virus: epidemiology,
468 clinical features and host-virus interactions. *Microbes and Infection* 2016;18:441–9.
469 doi:10.1016/j.micinf.2016.03.009.
- 470 [43] Brasil P, Pereira JP, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et al. Zika
471 Virus Infection in Pregnant Women in Rio de Janeiro. *N Engl J Med* 2016;375:2321–34.
472 doi:10.1056/NEJMoa1602412.
- 473 [44] de Fatima Vasco Aragao M, van der Linden V, Brainer-Lima AM, Coeli RR, Rocha MA, Sobral da
474 Silva P, et al. Clinical features and neuroimaging (CT and MRI) findings in presumed Zika virus
475 related congenital infection and microcephaly: retrospective case series study. *BMJ*
476 2016;353:i1901. doi:10.1136/bmj.i1901.
- 477 [45] Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al.
478 Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective
479 study. *The Lancet* 2016;387:2125–32. doi:10.1016/S0140-6736(16)00651-6.
- 480 [46] Carteaux G, Maquart M, Bedet A, Contou D, Brugières P, Fourati S, et al. Zika Virus Associated
481 with Meningoencephalitis. *New England Journal of Medicine* 2016;374:1595–6.
482 doi:10.1056/NEJMc1602964.
- 483 [47] Brasil P, Sequeira PC, Freitas AD, Zogbi HE, Calvet GA, de Souza RV, et al. Guillain-Barré
484 syndrome associated with Zika virus infection. *Lancet* 2016;387:1482. doi:10.1016/S0140-
485 6736(16)30058-7.
- 486 [48] Barbi L, Coelho AVC, Alencar LCA de, Crovella S. Prevalence of Guillain-Barré syndrome among
487 Zika virus infected cases: a systematic review and meta-analysis. *The Brazilian Journal of*
488 *Infectious Diseases* 2018;22:137–41. doi:10.1016/j.bjid.2018.02.005.
- 489 [49] Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *The Lancet* 2016;388:717–27.
490 doi:10.1016/S0140-6736(16)00339-1.
- 491 [50] Lynch RM, Mantus G, Encinales L, Pacheco N, Li G, Porras A, et al. Augmented Zika and Dengue
492 Neutralizing Antibodies Are Associated With Guillain-Barré Syndrome. *The Journal of Infectious*
493 *Diseases* 2019;219:26–30. doi:10.1093/infdis/jiy466.

- 494 [51] Chang AY, Lynch R, Martins K, Encinales L, Cadena Bonfanti AÁ, Pacheco N, et al. Long-term
495 clinical outcomes of Zika-associated Guillain-Barré syndrome. *Emerging Microbes & Infections*
496 2018;7. doi:10.1038/s41426-018-0151-9.
- 497 [52] Pena LJ, Miranda Guarines K, Duarte Silva AJ, Sales Leal LR, Mendes Félix D, Silva A, et al. In
498 vitro and in vivo models for studying Zika virus biology. *Journal of General Virology*
499 2018;99:1529–50. doi:10.1099/jgv.0.001153.
- 500 [53] Morrison TE, Diamond MS. Animal Models of Zika Virus Infection, Pathogenesis, and Immunity.
501 *Journal of Virology* 2017;91. doi:10.1128/JVI.00009-17.
- 502 [54] Miner JJ, Diamond MS. Zika Virus Pathogenesis and Tissue Tropism. *Cell Host Microbe*
503 2017;21:134–42. doi:10.1016/j.chom.2017.01.004.
- 504 [55] Dowall SD, Graham VA, Rayner E, Atkinson B, Hall G, Watson RJ, et al. A Susceptible Mouse
505 Model for Zika Virus Infection. *PLOS Neglected Tropical Diseases* 2016;10:e0004658.
506 doi:10.1371/journal.pntd.0004658.
- 507 [56] Rossi SL, Tesh RB, Azar SR, Muruato AE, Hanley KA, Auguste AJ, et al. Characterization of a
508 Novel Murine Model to Study Zika Virus. *Am J Trop Med Hyg* 2016;94:1362–9.
509 doi:10.4269/ajtmh.16-0111.
- 510 [57] Dowall SD, Graham VA, Rayner E, Hunter L, Atkinson B, Pearson G, et al. Lineage-dependent
511 differences in the disease progression of Zika virus infection in type-I interferon receptor
512 knockout (A129) mice. *PLOS Neglected Tropical Diseases* 2017;11:e0005704.
513 doi:10.1371/journal.pntd.0005704.
- 514 [58] Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, et al. A Mouse Model of Zika
515 Virus Pathogenesis. *Cell Host Microbe* 2016;19:720–30. doi:10.1016/j.chom.2016.03.010.
- 516 [59] Coffey LL, Keesler RI, Pesavento PA, Woolard K, Singapuri A, Watanabe J, et al. Intraamniotic
517 Zika virus inoculation of pregnant rhesus macaques produces fetal neurologic disease. *Nature*
518 *Communications* 2018;9. doi:10.1038/s41467-018-04777-6.
- 519 [60] Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, et al. Biology of Zika
520 Virus Infection in Human Skin Cells. *Journal of Virology* 2015;89:8880–96.
521 doi:10.1128/JVI.00354-15.
- 522 [61] Chan JF-W, Yip CC-Y, Tsang JO-L, Tee K-M, Cai J-P, Chik KK-H, et al. Differential cell line
523 susceptibility to the emerging Zika virus: implications for disease pathogenesis, non-vector-
524 borne human transmission and animal reservoirs. *Emerging Microbes & Infections* 2016;5:e93–
525 e93. doi:10.1038/emi.2016.99.
- 526 [62] Matusali G, Houzet L, Satie A-P, Mahé D, Aubry F, Couderc T, et al. Zika virus infects human
527 testicular tissue and germ cells. *Journal of Clinical Investigation* 2018;128:4697–710.
528 doi:10.1172/JCI121735.
- 529 [63] Robinson CL, Chong ACN, Ashbrook AW, Jeng G, Jin J, Chen H, et al. Male germ cells support
530 long-term propagation of Zika virus. *Nat Commun* 2018;9:2090. doi:10.1038/s41467-018-
531 04444-w.
- 532 [64] Tsetsarkin KA, Maximova OA, Liu G, Kenney H, Teterina N, Bloom ME, et al. Routes of Zika virus
533 dissemination in the testis and epididymis of immunodeficient mice. *Nature Communications*
534 2018;9. doi:10.1038/s41467-018-07782-x.
- 535 [65] Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, et al. Zika Virus Infects Human Cortical
536 Neural Progenitors and Attenuates Their Growth. *Cell Stem Cell* 2016;18:587–90.
537 doi:10.1016/j.stem.2016.02.016.
- 538 [66] Li C, Xu D, Ye Q, Hong S, Jiang Y, Liu X, et al. Zika Virus Disrupts Neural Progenitor Development
539 and Leads to Microcephaly in Mice. *Cell Stem Cell* 2016;19:120–6.
540 doi:10.1016/j.stem.2016.04.017.
- 541 [67] Li H, Saucedo-Cuevas L, Regla-Nava JA, Chai G, Sheets N, Tang W, et al. Zika Virus Infects Neural
542 Progenitors in the Adult Mouse Brain and Alters Proliferation. *Cell Stem Cell* 2016.
543 doi:10.1016/j.stem.2016.08.005.

- 544 [68] Wu K-Y, Zuo G-L, Li X-F, Ye Q, Deng Y-Q, Huang X-Y, et al. Vertical transmission of Zika virus
545 targeting the radial glial cells affects cortex development of offspring mice. *Cell Res*
546 2016;26:645–54. doi:10.1038/cr.2016.58.
- 547 [69] Pierson TC, Diamond MS. The emergence of Zika virus and its new clinical syndromes. *Nature*
548 2018;560:573–81. doi:10.1038/s41586-018-0446-y.
- 549 [70] Merfeld E, Ben-Avi L, Kennon M, Cerveny KL. Potential mechanisms of Zika-linked microcephaly:
550 Zika-linked microcephaly. *Wiley Interdisciplinary Reviews: Developmental Biology* 2017;6:e273.
551 doi:10.1002/wdev.273.
- 552 [71] Meertens L, Labeau A, Dejarnac O, Cipriani S, Sinigaglia L, Bonnet-Madin L, et al. Axl Mediates
553 ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses. *Cell Reports*
554 2017;18:324–33. doi:10.1016/j.celrep.2016.12.045.
- 555 [72] Richard AS, Shim B-S, Kwon Y-C, Zhang R, Otsuka Y, Schmitt K, et al. AXL-dependent infection of
556 human fetal endothelial cells distinguishes Zika virus from other pathogenic flaviviruses. *Proc*
557 *Natl Acad Sci USA* 2017;114:2024–9. doi:10.1073/pnas.1620558114.
- 558 [73] Chen J, Yang Y-F, Yang Y, Zou P, Chen J, He Y, et al. AXL promotes Zika virus infection in
559 astrocytes by antagonizing type I interferon signalling. *Nat Microbiol* 2018;3:302–9.
560 doi:10.1038/s41564-017-0092-4.
- 561 [74] Laureti M, Narayanan D, Rodriguez-Andres J, Fazakerley JK, Kedziarski L. Flavivirus Receptors:
562 Diversity, Identity, and Cell Entry. *Frontiers in Immunology* 2018;9.
563 doi:10.3389/fimmu.2018.02180.
- 564 [75] Lee I, Bos S, Li G, Wang S, Gadea G, Desprès P, et al. Probing Molecular Insights into Zika Virus–
565 Host Interactions. *Viruses* 2018;10:233. doi:10.3390/v10050233.
- 566 [76] Gong D, Zhang T-H, Zhao D, Du Y, Chapa TJ, Shi Y, et al. High-Throughput Fitness Profiling of Zika
567 Virus E Protein Reveals Different Roles for Glycosylation during Infection of Mammalian and
568 Mosquito Cells. *IScience* 2018;1:97–111. doi:10.1016/j.isci.2018.02.005.
- 569 [77] Wang Z-Y, Wang Z, Zhen Z-D, Feng K-H, Guo J, Gao N, et al. Axl is not an indispensable factor for
570 Zika virus infection in mice. *J Gen Virol* 2017;98:2061–8. doi:10.1099/jgv.0.000886.
- 571 [78] Wells MF, Salick MR, Wiskow O, Ho DJ, Worringer KA, Ihry RJ, et al. Genetic Ablation of AXL
572 Does Not Protect Human Neural Progenitor Cells and Cerebral Organoids from Zika Virus
573 Infection. *Cell Stem Cell* 2016;19:703–8. doi:10.1016/j.stem.2016.11.011.
- 574 [79] Frumence E, Roche M, Krejbich-Trotot P, El-Kalamouni C, Nativel B, Rondeau P, et al. The South
575 Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading
576 to IFN- β production and apoptosis induction. *Virology* 2016;493:217–26.
577 doi:10.1016/j.virol.2016.03.006.
- 578 [80] Savidis G, Perreira JM, Portmann JM, Meraner P, Guo Z, Green S, et al. The IFITMs Inhibit Zika
579 Virus Replication. *Cell Reports* 2016;15:2323–30. doi:10.1016/j.celrep.2016.05.074.
- 580 [81] Monel B, Compton AA, Bruel T, Amraoui S, Burlaud-Gaillard J, Roy N, et al. Zika virus induces
581 massive cytoplasmic vacuolization and paraptosis-like death in infected cells. *The EMBO Journal*
582 2017;36:1653–68. doi:10.15252/embj.201695597.
- 583 [82] Tripathi S, Balasubramaniam VRMT, Brown JA, Mena I, Grant A, Bardina SV, et al. A novel Zika
584 virus mouse model reveals strain specific differences in virus pathogenesis and host
585 inflammatory immune responses. *PLOS Pathogens* 2017;13:e1006258.
586 doi:10.1371/journal.ppat.1006258.
- 587 [83] Caine EA, Scheaffer SM, Arora N, Zaitsev K, Artyomov MN, Coyne CB, et al. Interferon lambda
588 protects the female reproductive tract against Zika virus infection. *Nature Communications*
589 2019;10. doi:10.1038/s41467-018-07993-2.
- 590 [84] Bayer A, Lennemann NJ, Ouyang Y, Bramley JC, Morosky S, Marques ETDA, et al. Type III
591 Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus
592 Infection. *Cell Host & Microbe* 2016;19:705–12. doi:10.1016/j.chom.2016.03.008.
- 593 [85] Jagger BW, Miner JJ, Cao B, Arora N, Smith AM, Kovacs A, et al. Gestational Stage and IFN- λ
594 Signaling Regulate ZIKV Infection In Utero. *Cell Host & Microbe* 2017;22:366-376.e3.
595 doi:10.1016/j.chom.2017.08.012.

- 596 [86] Kumar A, Hou S, Airo AM, Limonta D, Mancinelli V, Branton W, et al. Zika virus inhibits type-I
597 interferon production and downstream signaling. *EMBO Reports* 2016;17:1766–75.
598 doi:10.15252/embr.201642627.
- 599 [87] Bowen JR, Quicke KM, Maddur MS, O’Neal JT, McDonald CE, Fedorova NB, et al. Zika Virus
600 Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells. *PLOS*
601 *Pathogens* 2017;13:e1006164. doi:10.1371/journal.ppat.1006164.
- 602 [88] Xia H, Luo H, Shan C, Muruato AE, Nunes BT, Medeiros DBA, et al. An evolutionary NS1
603 mutation enhances Zika virus evasion of host interferon induction. *Nature Communications*
604 2018;9. doi:10.1038/s41467-017-02816-2.
- 605 [89] Grant A, Ponia SS, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, et al. Zika Virus
606 Targets Human STAT2 to Inhibit Type I Interferon Signaling. *Cell Host Microbe* 2016;19:882–90.
607 doi:10.1016/j.chom.2016.05.009.
- 608 [90] Ding Q, Gaska JM, Douam F, Wei L, Kim D, Balev M, et al. Species-specific disruption of STING-
609 dependent antiviral cellular defenses by the Zika virus NS2B3 protease. *Proceedings of the*
610 *National Academy of Sciences* 2018;115:E6310–8. doi:10.1073/pnas.1803406115.
- 611 [91] Onorati M, Li Z, Liu F, Sousa AMM, Nakagawa N, Li M, et al. Zika Virus Disrupts Phospho-TBK1
612 Localization and Mitosis in Human Neuroepithelial Stem Cells and Radial Glia. *Cell Rep*
613 2016;16:2576–92. doi:10.1016/j.celrep.2016.08.038.
- 614 [92] Göertz GP, Abbo SR, Fros JJ, Pijlman GP. Functional RNA during Zika virus infection. *Virus*
615 *Research* 2017. doi:10.1016/j.virusres.2017.08.015.
- 616 [93] Akiyama BM, Laurence HM, Massey AR, Costantino DA, Xie X, Yang Y, et al. Zika virus produces
617 noncoding RNAs using a multi-pseudoknot structure that confounds a cellular exonuclease.
618 *Science* 2016;354:1148–52. doi:10.1126/science.aah3963.
- 619 [94] Donald CL, Brennan B, Cumberworth SL, Rezelj VV, Clark JJ, Cordeiro MT, et al. Full Genome
620 Sequence and sfRNA Interferon Antagonist Activity of Zika Virus from Recife, Brazil. *PLOS*
621 *Neglected Tropical Diseases* 2016;10:e0005048. doi:10.1371/journal.pntd.0005048.
- 622 [95] Soto-Acosta R, Xie X, Shan C, Baker CK, Shi P-Y, Rossi SL, et al. Fragile X mental retardation
623 protein is a Zika virus restriction factor that is antagonized by subgenomic flaviviral RNA. *ELife*
624 2018;7. doi:10.7554/eLife.39023.
- 625 [96] Dang J, Tiwari SK, Lichinchi G, Qin Y, Patil VS, Eroshkin AM, et al. Zika Virus Depletes Neural
626 Progenitors in Human Cerebral Organoids through Activation of the Innate Immune Receptor
627 TLR3. *Cell Stem Cell* 2016;19:258–65. doi:10.1016/j.stem.2016.04.014.
- 628 [97] Azevedo RSS, de Sousa JR, Araujo MTF, Martins Filho AJ, de Alcantara BN, Araujo FMC, et al. In
629 situ immune response and mechanisms of cell damage in central nervous system of fatal cases
630 microcephaly by Zika virus. *Sci Rep* 2018;8:1. doi:10.1038/s41598-017-17765-5.
- 631 [98] Halstead SB. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. *Microbiol*
632 *Spectr* 2014;2. doi:10.1128/microbiolspec.AID-0022-2014.
- 633 [99] Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, et al. Human
634 antibody responses after dengue virus infection are highly cross-reactive to Zika virus.
635 *Proceedings of the National Academy of Sciences* 2016;113:7852–7.
636 doi:10.1073/pnas.1607931113.
- 637 [100] Regla-Nava JA, Elong Ngono A, Viramontes KM, Huynh A-T, Wang Y-T, Nguyen A-VT, et al.
638 Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy.
639 *Nature Communications* 2018;9. doi:10.1038/s41467-018-05458-0.
- 640 [101] Gordon A, Gresh L, Ojeda S, Katzelnick LC, Sanchez N, Mercado JC, et al. Prior dengue virus
641 infection and risk of Zika: A pediatric cohort in Nicaragua. *PLOS Medicine* 2019;16:e1002726.
642 doi:10.1371/journal.pmed.1002726.
- 643 [102] Pantoja P, Pérez-Guzmán EX, Rodríguez IV, White LJ, González O, Serrano C, et al. Zika virus
644 pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus.
645 *Nature Communications* 2017;8:15674. doi:10.1038/ncomms15674.

- 646 [103] Fowler AM, Tang WW, Young MP, Mamidi A, Viramontes KM, McCauley MD, et al. Maternally
647 Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice. *Cell Host & Microbe*
648 2018;24:743-750.e5. doi:10.1016/j.chom.2018.09.015.
- 649 [104] Rey FA, Stiasny K, Vaney M, Dellarole M, Heinz FX. The bright and the dark side of human
650 antibody responses to flaviviruses: lessons for vaccine design. *EMBO Reports* 2018;19:206–24.
651 doi:10.15252/embr.201745302.
- 652 [105] Saiz J-C, Oya N, Blázquez A-B, Escribano-Romero E, Martín-Acebes M. Host-Directed Antivirals:
653 A Realistic Alternative to Fight Zika Virus. *Viruses* 2018;10:453. doi:10.3390/v10090453.
- 654 [106] da Silva S, Oliveira Silva Martins D, Jardim A. A Review of the Ongoing Research on Zika Virus
655 Treatment. *Viruses* 2018;10:255. doi:10.3390/v10050255.
- 656 [107] Abrams RPM, Solis J, Nath A. Therapeutic Approaches for Zika Virus Infection of the Nervous
657 System. *Neurotherapeutics* 2017;14:1027–48. doi:10.1007/s13311-017-0575-2.
- 658 [108] Tabata T, Petitt M, Puerta-Guardo H, Michlmayr D, Wang C, Fang-Hoover J, et al. Zika Virus
659 Targets Different Primary Human Placental Cells, Suggesting Two Routes for Vertical
660 Transmission. *Cell Host & Microbe* 2016;20:155–66. doi:10.1016/j.chom.2016.07.002.
- 661 [109] Albulescu IC, Kovacikova K, Tas A, Snijder EJ, van Hemert MJ. Suramin inhibits Zika virus
662 replication by interfering with virus attachment and release of infectious particles. *Antiviral Res*
663 2017;143:230–6. doi:10.1016/j.antiviral.2017.04.016.
- 664 [110] Tan CW, Sam I-C, Chong WL, Lee VS, Chan YF. Polysulfonate suramin inhibits Zika virus
665 infection. *Antiviral Res* 2017;143:186–94. doi:10.1016/j.antiviral.2017.04.017.
- 666 [111] Rausch K, Hackett BA, Weinbren NL, Reeder SM, Sadovsky Y, Hunter CA, et al. Screening
667 Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus. *Cell*
668 *Reports* 2017;18:804–15. doi:10.1016/j.celrep.2016.12.068.
- 669 [112] Yu Y, Deng Y-Q, Zou P, Wang Q, Dai Y, Yu F, et al. A peptide-based viral inactivator inhibits Zika
670 virus infection in pregnant mice and fetuses. *Nature Communications* 2017;8:15672.
671 doi:10.1038/ncomms15672.
- 672 [113] Li C, Deng Y-Q, Wang S, Ma F, Aliyari R, Huang X-Y, et al. 25-Hydroxycholesterol Protects Host
673 against Zika Virus Infection and Its Associated Microcephaly in a Mouse Model. *Immunity*
674 2017;46:446–56. doi:10.1016/j.immuni.2017.02.012.
- 675 [114] Yuan S, Chan JF-W, den-Haan H, Chik KK-H, Zhang AJ, Chan CC-S, et al. Structure-based
676 discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently
677 inhibit Zika virus infection in vitro and in vivo. *Antiviral Research* 2017;145:33–43.
678 doi:10.1016/j.antiviral.2017.07.007.
- 679 [115] Chan JF-W, Chik KK-H, Yuan S, Yip CC-Y, Zhu Z, Tee K-M, et al. Novel antiviral activity and
680 mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. *Antiviral Res*
681 2017;141:29–37. doi:10.1016/j.antiviral.2017.02.002.
- 682 [116] Sacramento CQ, de Melo GR, de Freitas CS, Rocha N, Hoelz LVB, Miranda M, et al. The clinically
683 approved antiviral drug sofosbuvir inhibits Zika virus replication. *Scientific Reports* 2017;7.
684 doi:10.1038/srep40920.
- 685 [117] Bullard-Feibelman KM, Govero J, Zhu Z, Salazar V, Veselinovic M, Diamond MS, et al. The FDA-
686 approved drug sofosbuvir inhibits Zika virus infection. *Antiviral Res* 2017;137:134–40.
687 doi:10.1016/j.antiviral.2016.11.023.
- 688 [118] Ferreira AC, Zaverucha-do-Valle C, Reis PA, Barbosa-Lima G, Vieira YR, Mattos M, et al.
689 Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term
690 sequelae. *Sci Rep* 2017;7:9409. doi:10.1038/s41598-017-09797-8.
- 691 [119] Xu M, Lee EM, Wen Z, Cheng Y, Huang W-K, Qian X, et al. Identification of small-molecule
692 inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.
693 *Nature Medicine* 2016;22:1101–7. doi:10.1038/nm.4184.
- 694 [120] Wichit S, Hamel R, Bernard E, Talignani L, Diop F, Ferraris P, et al. Imipramine Inhibits
695 Chikungunya Virus Replication in Human Skin Fibroblasts through Interference with
696 Intracellular Cholesterol Trafficking. *Scientific Reports* 2017;7. doi:10.1038/s41598-017-03316-
697 5.

- 698 [121] Taguwa S, Yeh M-T, Rainbolt TK, Nayak A, Shao H, Gestwicki JE, et al. Zika Virus Dependence on
699 Host Hsp70 Provides a Protective Strategy against Infection and Disease. *Cell Rep* 2019;26:906-
700 920.e3. doi:10.1016/j.celrep.2018.12.095.
- 701 [122] Wang S, Hong S, Deng Y-Q, Ye Q, Zhao L-Z, Zhang F-C, et al. Transfer of convalescent serum to
702 pregnant mice prevents Zika virus infection and microcephaly in offspring. *Cell Research*
703 2017;27:158–60. doi:10.1038/cr.2016.144.
- 704 [123] Sapparapu G, Fernandez E, Kose N, Bin Cao, Fox JM, Bombardi RG, et al. Neutralizing human
705 antibodies prevent Zika virus replication and fetal disease in mice. *Nature* 2016;540:443–7.
706 doi:10.1038/nature20564.
- 707 [124] Wang J, Bardelli M, Espinosa DA, Pedotti M, Ng T-S, Bianchi S, et al. A Human Bi-specific
708 Antibody against Zika Virus with High Therapeutic Potential. *Cell* 2017;171:229-241.e15.
709 doi:10.1016/j.cell.2017.09.002.
- 710 [125] Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL, Kalil J. Development of vaccines
711 against Zika virus. *The Lancet Infectious Diseases* 2018;18:e211–9. doi:10.1016/S1473-
712 3099(18)30063-X.
- 713 [126] Dudley DM, Aliota MT, Mohr EL, Weiler AM, Lehrer-Brey G, Weisgrau KL, et al. A rhesus
714 macaque model of Asian-lineage Zika virus infection. *Nature Communications* 2016;7.
715 doi:10.1038/ncomms12204.
- 716 [127] Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. *Nature Reviews Microbiology*
717 2018;16:594–600. doi:10.1038/s41579-018-0039-7.
- 718 [128] Masmajan S, Baud D, Musso D, Panchaud A. Zika virus, vaccines, and antiviral strategies. *Expert*
719 *Review of Anti-Infective Therapy* 2018;16:471–83. doi:10.1080/14787210.2018.1483239.
- 720 [129] Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, et al. Protective
721 efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. *Science*
722 2016;353:1129–32. doi:10.1126/science.aah6157.
- 723 [130] Larocca RA, Abbink P, Peron JPS, de A. Zanutto PM, Iampietro MJ, Badamchi-Zadeh A, et al.
724 Vaccine protection against Zika virus from Brazil. *Nature* 2016;536:474–8.
725 doi:10.1038/nature18952.
- 726 [131] Abbasi J. Zika Vaccine Enters Clinical Trials. *JAMA* 2016;316:1249.
727 doi:10.1001/jama.2016.12760.
- 728 [132] Dowd KA, Ko S-Y, Morabito KM, Yang ES, Pelc RS, DeMaso CR, et al. Rapid development of a
729 DNA vaccine for Zika virus. *Science* 2016;354:237–40. doi:10.1126/science.aai9137.
- 730 [133] Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection
731 by a single low-dose nucleoside-modified mRNA vaccination. *Nature* 2017;543:248–51.
732 doi:10.1038/nature21428.
- 733 [134] Dyer O. Trials of Zika vaccine are set to begin in North America. *BMJ* 2016:i3588.
734 doi:10.1136/bmj.i3588.
- 735 [135] Xu K, Song Y, Dai L, Zhang Y, Lu X, Xie Y, et al. Recombinant Chimpanzee Adenovirus Vaccine
736 AdC7-M/E Protects against Zika Virus Infection and Testis Damage. *Journal of Virology* 2018;92.
737 doi:10.1128/JVI.01722-17.
- 738 [136] Durbin A. Vaccine Development for Zika Virus—Timelines and Strategies. *Seminars in*
739 *Reproductive Medicine* 2016;34:299–304. doi:10.1055/s-0036-1592070.
- 740 [137] Venter M. Assessing the zoonotic potential of arboviruses of African origin. *Current Opinion in*
741 *Virology* 2018;28:74–84. doi:10.1016/j.coviro.2017.11.004.
- 742

743

744 LEGENDS

745 **Figure 1. Strategies to control ZIKV infection in humans**


746 Innovative strategies to limit ZIKV transmission through the control and the reduction of *Aedes*
747 mosquito populations (1); the production of antiviral drugs able to inhibit ZIKV infection in humans
748 (2) and the development of efficient ZIKV vaccines to counteract ZIKV epidemy propagation (3). Red
749 spots represent organs from which ZIKV has been isolated.

750 **Table 1. Promising ZIKV antiviral drugs and vaccines**

751


1-Vector Control

- Wolbachia
- Larvicides
- Spatial repellent
- Insect traps
- Biotechnology-based sterile insect techniques
- Attractive targeted sugar baits
- Insecticide-treated materials
- Gene drives



3- Vaccines

- Inactivated virus
- Nucleic acid vaccines
- Adenovirus-based vaccines



Vertical transmission

Sexual transmission

2-Treatments



1- Attachment

- Suramin
- Duramycin
- AXL
- Other receptors ?

2- Entry

- Nanchangmycin
- 25HC
- Z2

3- replication


- Novobiocin
- Lopinavir-ritonavir
- Bromocriptine
- Sofosbuvir
- Imipramine

Nucleus

Therapeutic antibodies

4- Morphogenesis

Virions



Treatment	Target	system of validation	reference
Duramycin	viral entry	<i>in vitro</i>	104-106
Suramin	viral entry	<i>in vitro</i>	104-106
Nanchangmycin	viral entry	<i>in vitro</i>	107
Z2	viral entry	<i>in vitro/in vivo</i>	108
25HC	viral entry	<i>in vitro/in vivo</i>	109
Novobiocin	NS2B-NS3	<i>in silico/in vitro</i>	110
Lopinavir-ritonavir	NS2B-NS3	<i>in silico/in vitro</i>	110
Bromocriptine	NS2B-NS3	<i>in vitro</i>	111
Sofosbuvir	NS5 RdRp	<i>in silico/in vitro</i>	89,104-106
Emricasan	caspase 3	<i>in vitro</i>	115
Imipramine	cholesterol transport	<i>in vitro</i>	116
therapeutics antibodies	E	<i>in vitro/in vivo</i>	117-119
Vaccine	target	clinal trial	reference
inactivated virus	prM & E	phase I	122.125
nucleic acid vaccine	prM & E	phase I/II	122-129
adenovirus-based vaccine	prM & E	phase I	124,130